Key points from article :
Remedium Bio has secured an investment from Healthspan Capital, a venture capital fund specializing in longevity and regenerative medicine. Healthspan Capital brings extensive experience in funding innovative biotech start-ups, positioning itself at the forefront of the rapidly growing longevity sector, which saw over $3 billion in investments in 2021.
The funding will support the development of RMD-1202, Remedium’s gene therapy for type 2 diabetes and obesity. This therapy is built on Prometheus™, the company’s adjustable-dose gene therapy platform, which enables a single, subcutaneous injection to deliver stable and long-lasting therapeutic proteins. By avoiding pharmacokinetic spikes, this approach may reduce side effects while improving treatment outcomes at a lower cost than traditional protein therapies.
Sebastian Brunemeier, General Partner at Healthspan Capital, emphasized the potential of gene therapy for aging and age-related diseases, noting that Remedium’s platform allows for affordable, self-sustained therapeutic production, even in regions where advanced treatments have been inaccessible. Frank Luppino, CEO of Remedium, welcomed the investment, highlighting its role in accelerating the company’s lead program and expanding Prometheus™ to new therapeutic areas.
